- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02773875
Fault Detection, Zone MPC and DiAs System in T1D (ZoneMPC)
A Randomized Crossover Study to Evaluate the Efficacy of Fault Detection Algorithms Using the ZoneMPC Algorithm and DiAs System in Adult Subjects With Type 1 Diabetes in the Outpatient Setting
연구 개요
상세 설명
Investigational Device:
Artificial Pancreas System with Fault Detection Algorithms: Roche Accu-Check Spirit Combo Insulin Pump, Dexcom G4P System with Share, Diabetes Assistant (DiAs) on Android phone, DiAs Web Monitoring (DWM)
- referred to as Remote Monitoring Server, MPC control algorithm, Health Monitoring System (HMS) algorithm. Sensor and infusion set fault detection algorithms will be applied offline with data obtained from server and notifications will be sent to the clinician.
Control Arm:
Sensor-augmented insulin pump therapy: Subject will use their personal insulin pump and Dexcom G4P System with Share.
Primary Objective:
To determine the efficacy of the fault detection algorithm. The primary outcome is based on the amount of time the sensor glucose is >250 mg/dL in the 4 hours preceding detection of the infusion set failure during sensor augmented pump therapy vs. closed-loop control with fault detection alerts.
Secondary Objectives:
To determine the effectiveness of the sensor fault detection algorithm. To determine the efficacy of the Zone MPC controller by evaluating glycemic outcomes
Number of Subjects:
There will be 20 subjects recruited: 10 at Stanford and 10 at Denver (up to 36 subjects will be enrolled to reach 20 subjects completing the study)
Diagnosis and Main Inclusion Criteria:
Adult subjects between 18 and 55 years of age inclusive, diagnosed with type 1 diabetes.
Trial Design:
This outpatient study will be conducted over 6 weeks as shown in the figure below. The 6-week period will consist of two 2-week blocks of prolonged infusion set wear with a 1-week sensor run-in period preceding each block. In each block, subjects will wear an infusion set for up to 7 days. A new infusion set will be inserted at the start of each week in the block. Following enrollment procedures, subjects will be randomized at a ratio of 1:1 to either use the AP system with fault detection algorithms (intervention) or sensor-augmented pump therapy (control) in the first block.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: David Maahs, MD, PhD
- 이메일: David.Maahs@ucdenver.edu
연구 연락처 백업
- 이름: Laurel Messer
- 이메일: Laurel.Messer@ucdenver.edu
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Clinical diagnosis of type 1 diabetes for at least 12 months
- Daily insulin therapy for at least 12 months
- Age between 18.0 to 55.0 years of age
- Use of an insulin pump for at least 3 months
- Subject comprehends English
- Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test
- Total daily insulin requirement ≥ 0.3 units/kg/day
- Subject has an adult companion, age > 18 years, who lives with the subject, has access to where they sleep, is willing to be in the house when the subject is sleeping and willing to attend to the subject if there are safety concerns -
Exclusion Criteria:
- Diabetic ketoacidosis in the past 6 months
- Hypoglycemic seizure or loss of consciousness in the past 6 months
- Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
- Subjects using other anti-diabetic medications other than insulin (oral or injectable) at the time of enrollment. Any prior use of other anti-diabetic medications must be washed out for at least 8 weeks prior to enrollment.
- Current use of other medications, which in the judgment of the investigator would be a contraindication to participation in the study
- Subject has a medical disorder that in the judgment of the investigator will affect completion of any aspect of the protocol
- Subject is currently participating in another investigational device or drug study within 30 days or 5-half-lives of the drug.
- Subject has a history of any cardiac or vascular disorder including, but not limited to, myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
- Subject has a history of hepatic disease
- Subject has renal failure on dialysis
- Systolic blood pressure > 160 mmHg on screening visit
- Diastolic blood pressure > 90 mmHg on screening visit
- Subjects with inadequately treated thyroid disease or celiac disease
- Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
- Subject has received inpatient psychiatric treatment in the past 6 months
- Subject consumes more than an average of 4 standard alcoholic drinks/day in the last 30 days
- Subject has an active skin condition that would affect sensor placement
- Subject is unable to avoid acetaminophen for the duration of the study
- Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
- Subject is currently on beta blocker medication -
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
간섭 없음: Sensor Augmented Pump (control)
Use sensor augmented pump (SAP) for 3 weeks.
|
|
실험적: Artificial Pancreas (intervention)
Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
|
The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Amount of time sensor glucose levels are >250 mg/dl
기간: 4 hours after insulin infusion set failure
|
Amount of time sensor glucose levels are >250 mg/dl in the control arm versus the experimental arm
|
4 hours after insulin infusion set failure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Effectiveness of sensor fault detection algorithm as defined by % of sensor failures caught by the system
기간: During 2 week intervention period
|
Effectiveness of sensor fault detection algorithm as defined by % of sensor failures caught by the system
|
During 2 week intervention period
|
Mean sensor glucose values
기간: 2 week intervention period versus 2 week control period
|
mean sensor glucose values
|
2 week intervention period versus 2 week control period
|
Percent of time in range between 70-180 mg/dl
기간: 2 week intervention period versus 2 week control period
|
Percent of time in range between 70-180 mg/dl
|
2 week intervention period versus 2 week control period
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Howsmon DP, Baysal N, Buckingham BA, Forlenza GP, Ly TT, Maahs DM, Marcal T, Towers L, Mauritzen E, Deshpande S, Huyett LM, Pinsker JE, Gondhalekar R, Doyle FJ 3rd, Dassau E, Hahn J, Bequette BW. Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas. J Diabetes Sci Technol. 2018 May;12(3):599-607. doi: 10.1177/1932296818755173. Epub 2018 Feb 1.
- Forlenza GP, Deshpande S, Ly TT, Howsmon DP, Cameron F, Baysal N, Mauritzen E, Marcal T, Towers L, Bequette BW, Huyett LM, Pinsker JE, Gondhalekar R, Doyle FJ 3rd, Maahs DM, Buckingham BA, Dassau E. Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. Diabetes Care. 2017 Aug;40(8):1096-1102. doi: 10.2337/dc17-0500. Epub 2017 Jun 5. Erratum In: Diabetes Care. 2017 Sep 8;:
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제1형 당뇨병에 대한 임상 시험
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈
-
Chong Kun Dang Pharmaceutical완전한
-
Sohag Universitysohag university hospital모병
-
Centre hospitalier de l'Université de Montréal...Maisonneuve-Rosemont Hospital모병Boston Keratoprosthesis Type I의 각막 용해캐나다
-
Xiang XieXinjiang Medical University아직 모집하지 않음암 | 죽상동맥경화성 심혈관 질환 | ASCVD | Proprotein Convertase Subtilisin/Kexin Type 9 억제제
-
University of Bologna완전한
-
Oxford Brookes UniversityUniversity of Oxford완전한신체 활동 | 정신 건강 웰니스 1 | 인지 기능 1, 사회적 | Academic Attainment | Fitness Testing영국
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National... 그리고 다른 협력자들완전한
-
Tianjin Chest Hospital모병급성관상동맥증후군 | Proprotein Convertase Subtilisin/Kexin Type 9 억제제중국
-
Postgraduate Institute of Medical Education and...완전한